Commentary|Videos|November 17, 2026

Pharmacists Can Help Overcome Clinical Inertia in CKD Care

Navdeep Tangri, MD, PhD, FRCP, says patients with stage G4+ CKD who stayed on GDMT did best, challenging the idea that it's too late to benefit from therapy.

In an interview with Pharmacy Times for Kidney Week 2026, Navdeep Tangri, MD, PhD, FRCP, professor of medicine at the University of Manitoba in Canada, discussed findings from an analysis of guideline-directed medical therapy (GDMT) and hospitalization risk in patients with stage G4+ chronic kidney disease (CKD). He also covered the role pharmacists can play in closing CKD treatment gaps and the need to shift care toward preventing late-stage disease.1

Key Takeaways

  • Don't assume it's too late at stage G4.
  • Address the patient side of clinical inertia.
  • Shift the focus to prevention.

Tangri explained that patients with stage G4+ CKD have lost more than 70%, and sometimes 80%, of their kidney function. At this stage, GDMT is often discontinued because of perceived or real adverse effects or a perceived lack of efficacy, as if, in his words, the horse has already left the barn. Tangri challenged that notion. He said high-risk patients with advanced CKD still benefit, and that patients who stayed on therapy did the best compared with those who discontinued, with staying on GDMT linked to fewer hospitalizations.

Tangri said clinical inertia has 2 parts. Physicians may view an asymptomatic patient as stable and hold off on therapy, and patients who feel well may question why they need another medication. He said pharmacists should be in the circle of care for patients with CKD. When equipped with risk stratification and a plain-language report, they can help address the patient side of that inertia. The conversation, he said, should shift from treating late-stage kidney disease to preventing it with the tools available today.

REFERENCE
1. Tangri N, Ferguson TW, Bhanushali GK, et al. Association of guideline-directed medical therapy and hospitalization risk in patients with CKD; Abstract FR-PO0287. Presented: American Society of Nephrology Kidney Week; Denver, CO; October 23, 2026. Accessed online November 9, 2026. https://mjh.sanity.studio/pharmacytimes/structure/article;aed28e01-c6de-4991-b7da-cfae2fc43b5a

Related to this article